On behalf of IFARA, Fred Schaich spoke with Kimberly Smith of ViiV Healthcare at this year's International AIDS Conference about 48-week data from the ARIA study of drug efficacy in women with HIV.
Genome engineering is an experimental approach for achieving a functional cure of HIV by genetically engineering CD4 T cells to become resistant to HIV, Paula Cannon, Ph.D., of the University of Southern California explained during a presentation at AS…
Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small proof-of-concept study present...
CROI 2016 provided a bevy of exciting updates in HIV prevention and treatment, with important developments in new PrEP modalities and sobering modeling of the current state of the epidemic.
Taking a long-acting injection of cabotegravir + rilpivirine (Edurant) either every four or eight weeks is safe and well tolerated while also maintaining high viral suppression rates, according to a CROI 2016 study.
U.S. CDC scientists presented more than 40 abstracts at CROI 2016 that highlighted new HIV research findings and its implications for HIV prevention efforts across the nation.
In this interview, Matthew Perkins, M.D., discusses the interest in post-treatment controllers -- people living with HIV who are able to control the virus for a period of time after stopping therapy -- and the first study such individuals.
With more than 20 approved HIV antiretrovirals in the United States, physicians have many options for their patients -- they can choose one of the "preferred" drug regimens or deviate from treatment guidelines entirely.
A new study finds significant health disparities between black and white men with HIV, even though these men had equal access to health care through the Veterans Administration (VA).
Women with HIV should receive not only the same antiretroviral therapy as men, but also clinical care tailored to their specific risk factors and health care goals, according to Kathleen Squires, M.D.